A 9-Year Experience of Aspergillus Infections from Isfahan, Iran

References

• Kan VL, Judson MA, Morrison VA, et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis. 2000;30:696–709. doi:10.1086/31375610770732
   PubMed Web of Science ®Google Scholar
• Kosmidis C, Denning DW. The clinical spectrum of pulmonary aspergillosis. Thorax. 2015;70:270–277. doi:10.1136/thoraxjnl-2014-20629125354514
   PubMed Web of Science ®Google Scholar
• Brown GD, Denning DW, Gow NAR, et al. Hidden killers: human fungal infections. Sci Transl Med. 2012;4:165rv13. doi:10.1126/scitranslmed.3004404
   PubMed Web of Science ®Google Scholar
• Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses study group education and Research Consortium. Clin Infect Dis. 2019. doi:10.1093/cid/ciz1008
   PubMed Web of Science ®Google Scholar
• Vidal-Acuña MR, Ruiz-pérez de Pipaón M, Torres-Sánchez MJ, Aznar J. Identification of clinical isolates of Aspergillus, including cryptic species, by matrix assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS). Med Mycol. 2018;56:838–846. doi:10.1093/mmy/myx11529228361
   PubMed Web of Science ®Google Scholar
• Samson RA, Hong S-B, Frisvad JC. Old and new concepts of species differentiation in Aspergillus. Med Mycol. 2006;44:S133S148. doi:10.1080/13693780600913224
   Web of Science ®Google Scholar
• Steinbach WJ, Marr KA, Anaissie EJ, et al. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J Infect. 2012;65:453–464. doi:10.1016/j.jinf.2012.08.00322898389
   PubMed Web of Science ®Google Scholar
• Perfect J, Cox G, Lee J, et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis. 2001;33:1824–1833. doi:10.1086/32390011692293
   PubMed Web of Science ®Google Scholar
• Posch W, Blatzer M, Wilflingseder D, Lass-Flörl C. Aspergillus terreus: novel lessons learned on amphotericin B resistance. Med Mycol. 2018;56:S73S82. doi:10.1093/mmy/myx119
   Web of Science ®Google Scholar
• Balajee SA, Gribskov JL, Hanley E, Nickle D, Marr KA. Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus. Eukaryot Cell. 2005;4:625–632. doi:10.1128/EC.4.3.625-632.200515755924
   PubMed Web of Science ®Google Scholar
• Peterson SW, Ito Y, Horn BW, Goto T. Aspergillus bombycis, a new aflatoxigenic species and genetic variation in its sibling species, A. nomius. Mycologia. 2001;93:689–703. doi:10.1080/00275514.2001.12063200
   Web of Science ®Google Scholar
• Hubka V, Lyskova P, Frisvad JC, Peterson SW, Skorepova M, Kolarik M. Aspergillus pragensis sp. nov. discovered during molecular reidentification of clinical isolates belonging to Aspergillus section Candidi. Sabouraudia. 2014;52:565–576. doi:10.1093/mmy/myu022
   Google Scholar
• Zotti M, Agnoletti AF, Vizzini A, Cozzani E, Parodi A. Onychomycosis from Aspergillus melleus, a novel pathogen for humans. Fungal identification and in vitro drug susceptibility. Exp Dermatol. 2015;24:966–968. doi:10.1111/exd.1280726174422
   PubMed Web of Science ®Google Scholar
• Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med. 2012;125:S3S13. doi:10.1016/j.amjmed.2011.11.001
   Web of Science ®Google Scholar
• Gheith S, Saghrouni F, Bannour W, et al. In vitro susceptibility to amphotericin B, itraconazole, voriconazole, posaconazole and caspofungin of Aspergillus spp. isolated from patients with haematological malignancies in Tunisia. Springerplus. 2014;3:19. doi:10.1186/2193-1801-3-1926034655
   PubMedGoogle Scholar
• Lamoth F, Alexander BD. Comparing Etest and broth microdilution for antifungal susceptibility testing of the most-relevant pathogenic molds. J Clin Microbiol. 2015;53:3176–3181. doi:10.1128/JCM.00925-1526202113
   PubMed Web of Science ®Google Scholar
• Samson RA, Visagie CM, Houbraken J, et al. Phylogeny, identification and nomenclature of the genus Aspergillus. Stud Mycol. 2014;78:141–173. doi:10.1016/j.simyco.2014.07.00425492982
   PubMed Web of Science ®Google Scholar
• Schmidt A, Wolff M. Morphological characteristics of Aspergillus fumigatus strains isolated from patient samples. Mycoses. 1997;40:347–351. doi:10.1111/j.1439-0507.1997.tb00248.x9470420
   PubMed Web of Science ®Google Scholar
• Gnat S, Nowakiewicz A, Ziółkowska G, Trościańczyk A, Majer‐Dziedzic B, Zięba P. Evaluation of growth conditions and DNA extraction techniques used in the molecular analysis of dermatophytes. J Appl Microbiol. 2017;122:1368–1379. doi:10.1111/jam.1342728236353
   PubMed Web of Science ®Google Scholar
• Wayne P. Reference method for broth dilution antifungal susceptibility testing of yeasts, approved standard. CLSI document M27-A2. Clin Lab Stand Inst. 2002.
   Google Scholar
• Wayne P; National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. NNCLS document M27-A3. Clin Lab Stand Inst. 2008
   Google Scholar
• Jenks JD, Spiess B, Buchheidt D, Hoenigl M. (New) methods for detection of aspergillus fumigatus resistance in clinical samples. Curr Fungal Infect Rep. 2019;13:129–136. doi:10.1007/s12281-019-00342-w31552129
   PubMed Web of Science ®Google Scholar
• Fortún J, Meije Y, Fresco G, Moreno S. Aspergillosis. Clinical forms and treatment. Enferm Infecc Microbiol Clin. 2012;30:201–208. doi:10.1016/j.eimc.2011.12.00522341751
   PubMed Web of Science ®Google Scholar
• Alastruey‐Izquierdo A, Mellado E, Cuenca‐Estrella M. Current section and species complex concepts in Aspergillus: recommendations for routine daily practice. Ann N Y Acad Sci. 2012;1273:18–24. doi:10.1111/j.1749-6632.2012.06822.x23230833
   PubMed Web of Science ®Google Scholar
• Alastruey-Izquierdo A, Mellado E, Peláez T, et al. Population-based survey of filamentous fungi and antifungal resistance in Spain (FILPOP study). Antimicrob Agents Chemother. 2013;57:3380–3387. doi:10.1128/AAC.00383-1323669377
   PubMed Web of Science ®Google Scholar
• Balajee SA, Kano R, Baddley JW, et al. Molecular identification of Aspergillus species collected for the transplant-associated infection surveillance network. J Clin Microbiol. 2009;47:3138–3141. doi:10.1128/JCM.01070-0919675215
   PubMed Web of Science ®Google Scholar
• Negri C, Gonçalves S, Xafranski H, et al. Cryptic and rare Aspergillus species in Brazil: prevalence in clinical samples and in vitro susceptibility to triazoles. J Clin Microbiol. 2014;52:3633–3640. doi:10.1128/JCM.01582-1425078909
   PubMed Web of Science ®Google Scholar
• Krishnan S, Manavathu EK, Chandrasekar PH. Aspergillus flavus: an emerging non fumigatus Aspergillus species of significance. Mycoses. 2009;52:206–222. doi:10.1111/j.1439-0507.2008.01642.x19207851
   PubMed Web of Science ®Google Scholar
• Heo MS, Shin JH, Choi MJ, et al. Molecular identification and amphotericin B susceptibility testing of clinical isolates of Aspergillus from 11 hospitals in Korea. Ann Lab Med. 2015;35:602–610. doi:10.3343/alm.2015.35.6.60226354348
   PubMed Web of Science ®Google Scholar
• Zhou W, Li H, Zhang Y, et al. Diagnostic value of galactomannan antigen test in serum and bronchoalveolar lavage fluid samples from patients with nonneutropenic invasive pulmonary aspergillosis. J Clin Microbiol. 2017;55:2153–2161. doi:10.1128/JCM.00345-1728446576
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Pappas PG, Wingard JR. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis. 2006;43:S3S14. doi:10.1086/504490
   Web of Science ®Google Scholar
• Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus study group. Medicine. 2000;79:250–260. doi:10.1097/00005792-200007000-0000610941354
   PubMed Web of Science ®Google Scholar
• Veer P, Patwardhan N, Damle A. Study of onychomycosis: prevailing fungi and pattern of infection. Indian J Med Microbiol. 2007;25(1):53–56. doi:10.4103/0255-0857.3106317377354
   PubMedGoogle Scholar
• Wijesuriya T, Kottahachchi J, Gunasekara T, et al. Aspergillus species: an emerging pathogen in onychomycosis among diabetics. Indian J Endocrinol Metab. 2015;19:811–816. doi:10.4103/2230-8210.16756526693433
   PubMedGoogle Scholar
• Naghibzadeh B, Razmpa E, Alavi S, et al. Prevalence of fungal infection among Iranian patients with chronic sinusitis. Acta Otorhinolaryngol Ital. 2011;31:35–38.21808461
   PubMed Web of Science ®Google Scholar
• Ebadollahi-Natanzi A, Arab-Rahmatipour G, Tabatabaei SA. Prevalence of fungal keratitis (FK) in patients with corneal ulcers in Tehran, Iran. Asia Pacific J Med Toxi. 2016;5:94–97.
   Google Scholar
• Gharaghani M, Seifi Z, Mahmoudabadi AZ. Otomycosis in Iran: a review. Mycopathologia. 2015;179:415–424. doi:10.1007/s11046-015-9864-725633436
   PubMed Web of Science ®Google Scholar
• Pinto E, Monteiro C, Maia M, et al. Aspergillus species and antifungals susceptibility in clinical setting in the north of Portugal: cryptic species and emerging azoles resistance in A. fumigatus. Front Microbiol. 2018;9:1656. doi:10.3389/fmicb.2018.0165630083151
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A. Comparison of the E-test with the NCCLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi. J Clin Microbiol. 2001;39:1360–1367. doi:10.1128/JCM.39.4.1360-1367.200111283057
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A. Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991). J Clin Microbiol. 2003;41:403–409. doi:10.1128/JCM.41.1.403-409.200312517880
   PubMed Web of Science ®Google Scholar
• Fuller J, Schofield A, Jiwa S, Sand C, Jansen B, Rennie R. Caspofungin Etest endpoint for Aspergillus isolates shows poor agreement with the reference minimum effective concentration. J Clin Microbiol. 2010;48:479–482. doi:10.1128/JCM.01677-0920007389
   PubMed Web of Science ®Google Scholar
• Lass‐Flörl C, Griff K, Mayr A, et al. Epidemiology and outcome of infections due to Aspergillus terreus: 10‐year single centre experience. Br J Haematol. 2005;131:201–207. doi:10.1111/j.1365-2141.2005.05763.x16197450
   PubMed Web of Science ®Google Scholar
• Arikan S, Sancak B, Alp S, Hascelik G, Mcnicholas P. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus. Sabouraudia. 2008;46:567–573. doi:10.1080/13693780801975576
   Google Scholar
• Burgel P-R, Baixench M-T, Amsellem M, et al. High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole. Antimicrob Agents Chemother. 2012;56:869–874. doi:10.1128/AAC.05077-1122123701
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Dawson K, Pfaller M, et al. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother. 1995;39:314–319. doi:10.1128/AAC.39.2.3147726488
   PubMed Web of Science ®Google Scholar
• Ghannoum M, Chaturvedi V, Espinel-Ingroff A, et al. Intra-and interlaboratory study of a method for testing the antifungal susceptibilities of dermatophytes. J Clin Microbiol. 2004;42:2977–2979. doi:10.1128/JCM.42.7.2977-2979.200415243047
   PubMed Web of Science ®Google Scholar
• Alborzi A, Moeini M, Haddadi P. Antifungal susceptibility of the Aspergillus species by Etest and CLSI reference methods. Arch Iran Med. 2012;15:429–432.22724880
   PubMed Web of Science ®Google Scholar
• Johnson EM, Oakley KL, Radford SA, et al. Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. J Antimicrob Chemother. 2000;45:85–93. doi:10.1093/jac/45.1.8510629017
   PubMed Web of Science ®Google Scholar
• Van Der Linden JW, Warris A, Verweij PE. Aspergillus species intrinsically resistant to antifungal agents. Med Mycol. 2011;49:S82S89. doi:10.3109/13693786.2010.499916
   Web of Science ®Google Scholar
• Bueid A, Howard SJ, Moore CB, et al. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J Antimicrob Chemother. 2010;65:2116–2118. doi:10.1093/jac/dkq27920729241
   PubMed Web of Science ®Google Scholar
• van Ingen J, van der Lee HA, Rijs TA, et al. Azole, polyene and echinocandin MIC distributions for wild-type, TR34/L98H and TR46/Y121F/T289A Aspergillus fumigatus isolates in the Netherlands. J Antimicrob Chemother. 2015;70:178–181. doi:10.1093/jac/dku36425301884
   PubMed Web of Science ®Google Scholar
• Mortensen KL, Jensen RH, Johansen HK, et al. Aspergillus species and other molds in respiratory samples from patients with cystic fibrosis: a laboratory-based study with focus on Aspergillus fumigatus azole resistance. J Clin Microbiol. 2011;49:2243–2251. doi:10.1128/JCM.00213-1121508152
   PubMed Web of Science ®Google Scholar
• Nabili M, Shokohi T, Moazeni M, et al. High prevalence of clinical and environmental triazole-resistant Aspergillus fumigatus in Iran: is it a challenging issue? J Med Microbiol. 2016;65:468–475. doi:10.1099/jmm.0.00025527008655
   PubMed Web of Science ®Google Scholar
• Mohammadi F, Hashemi SJ, Seyedmousavi SM, Akbarzade D. Isolation and characterization of clinical triazole resistance Aspergillus fumigatus in Iran. Iran J Public Health. 2018;47:994–1000.30181998
   PubMed Web of Science ®Google Scholar
• Arendrup MC, Jensen RH, Grif K, et al. In vivo emergence of Aspergillus terreus with reduced azole susceptibility and a Cyp51a M217I alteration. J Infect Dis. 2012;206:981–985. doi:10.1093/infdis/jis44222782947
   PubMed Web of Science ®Google Scholar
• Verweij P, Van de Sande-bruisma N, Kema G, Melchers W. Azole resistance in Aspergillus fumigatus in the Netherlands increase due to environmental fungicides? Ned Tijdschr Geneeskd. 2012;156:A4458.22748367
   PubMedGoogle Scholar
• Morteza Z, Mousavi SB, Baghestani MA, Aitio A. An assessment of agricultural pesticide use in Iran, 20122014. J Environ Health Sci Eng. 2017;15:10. doi:10.1186/s40201-017-0272-428451437
   PubMed Web of Science ®Google Scholar
• Krishnan-Natesan S, Chandrasekar PH, Alangaden GJ, Manavathu EK. Molecular characterisation of cyp51A and cyp51B genes coding for P450 14α-lanosterol demethylases A (CYP51Ap) and B (CYP51Bp) from voriconazole-resistant laboratory isolates of Aspergillus flavus. Int J Antimicrob Agents. 2008;32:519–524. doi:10.1016/j.ijantimicag.2008.06.01818775650
   PubMed Web of Science ®Google Scholar
• Liu W, Sun Y, Chen W, et al. The T788G mutation in the cyp51C gene confers voriconazole resistance in Aspergillus flavus causing aspergillosis. Antimicrob Agents Chemother. 2012;56:2598–2603. doi:10.1128/AAC.05477-1122314539
   PubMed Web of Science ®Google Scholar
• Natesan SK, Lamichchane A, Swaminathan S, Wu W. Differential expression of ATP-binding cassette and/or major facilitator superfamily class efflux pumps contributes to voriconazole resistance in Aspergillus flavus. Diagn Microbiol Infect Dis. 2013;76:458–463. doi:10.1016/j.diagmicrobio.2013.04.02223886435
   PubMed Web of Science ®Google Scholar
• Verweij PE, Ananda-Rajah M, Andes D, et al. International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resist Updat. 2015;21:30–40. doi:10.1016/j.drup.2015.08.00126282594
   PubMed Web of Science ®Google Scholar
• Meis JF, Chowdhary A, Rhodes JL, Fisher MC, Verweij PE. Clinical implications of globally emerging azole resistance in Aspergillus fumigatus. Philos Trans R Soc Lond B Biol Sci. 2016;371:20150460. doi:10.1098/rstb.2015.046028080986
   PubMed Web of Science ®Google Scholar